reports
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demo...
NeuroNOS Announces Groundbreaking Research Publication by its CSO Demonstrating Mechanism of Action in Alzheimer’s Disease and Reinforcing Platform’s Strength Across Neurological Disorders BOSTON, April 01, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company developing transformative treatments for complex neurological disorders, including Autism Spectrum Disorder (ASD), brain cancers, and Alzheimer’s disease, and a subsidiary of Beyond Air (NASDAQ: XAIR), proudly announces the publication of breakthrough research by its Chief Scientific Officer, Prof. Haitham Amal, ...
Beyond Air Announces Vanderbilt University Medical Center as First Lum...
Beyond Air Announces Vanderbilt University Medical Center as First Luminary Site As the first Beyond Air luminary site, Vanderbilt will help evaluate and showcase the clinical and operational benefits of LungFit® PH, supporting broader awareness and adoption of tankless iNO technology GARDEN CITY, N.Y., March 31, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Vanderbilt Unive...
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an ...
NeuroNOS Secures $2.0 Million in Funding to Advance Development of an Innovative Autism Therapy First-in-human studies anticipated to begin in 2026 Engaged a top tier U.S. based contract manufacturer to ensure the highest standards of quality Currently in the advanced stages of formulation development for subcutaneous injection, with plans for an oral formulation BOSTON, March 24, 2025 (GLOBE NEWSWIRE) -- NeuroNOS, a pioneering biopharmaceutical company focused on developing transformative treatments for Autism Spectrum Disorder (ASD) and other complex neurological conditions, includin...
- Jonathan Moreland
PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
FRPT FRESHPET INC
HRTG HERITAGE INSURANCE HOLDINGS INC.
CULP CULP INC.
MAC MACERICH COMPANY
ORN ORION GROUP HOLDINGS
TREE LENDINGTREE INC.
NKSH NATIONAL BANKSHARES INC.
FLWS 1-800-FLOWERS.COM CL A
MX MAGNACHIP SEMICONDUCTOR CORP.
TCPC BLACKROCK TCP CAPITAL CORP.
XAIR BEYOND AIR
CMPR CIMPRESS PLC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
PRDO PERDOCEO EDUCATION CORP
FET FORUM ENERGY TECHNOLOGIES
SEAT VIVID SEATS INC.
FLNC FLUENCE ENERGY INC
BTMD HAYMAKER ACQUISITION CORP III
ECAT BLACKROCK ESG CAP ALLOCATION TR
ONL ORION OFFICE REIT INC
MLYS MINERALYS THERAPEUTICS INC
DK DELEK US HOLDINGS
CVI INC.
CUBA CVR ENERGY
SUNS INC.
AFCG THE HERZFELD CARIBBEAN BASIN FUND
INC.
SUNRISE REALTY TRUST
AFC GAMMA
INC.
Beyond Air Announces Agreements Expanding Global Distribution of LungF...
Beyond Air Announces Agreements Expanding Global Distribution of LungFit® PH Distribution agreements recently signed for France, Turkey, Romania and Morocco LungFit PH international distribution network now includes 18 countries Initial international orders for LungFit PH systems have been received for four countries GARDEN CITY, N.Y., March 11, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, ann...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferen...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences GARDEN CITY, N.Y., March 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in the Roth 37th Annual Growth Stock Conference being held March 16-18, 2025 in Laguna, CA and the Jones Healthcare and Technology Innovation Confere...
Gran Tierra Energy Inc. Announces 2024 Fourth Quarter & Year-End Resul...
Gran Tierra Energy Inc. Announces 2024 Fourth Quarter & Year-End Results Record Fourth Quarter Production of 41,009 BOEPDRealized 2024 Net Income of $3 Million ($0.10 per Share, Basic) and 2024 Adjusted EBITDA1 of $367 MillionDelivered Net Cash Provided by Operating Activities of $239.3 million, up 5% from 2023Generated 2024 Funds Flow from Operations1 of $225 Million and Achieved 2024 Average Working Interest Production of 34,710 BOEPD, up 6% from 2023Sixth Consecutive Year of 1P Total Company Reserves GrowthHighest Year-End Total Company Reserves in Company History - 167 MMBOE 1P, 293 MMB...
Paycom Software Inc: 1 director
A director at Paycom Software Inc sold 1,500 shares at 210.570USD and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Gran Tierra Energy Inc. Provides Release Date for its 2024 Fourth Quar...
Gran Tierra Energy Inc. Provides Release Date for its 2024 Fourth Quarter & Year End Results and Details of Conference Call and Webcast CALGARY, Alberta, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Gran Tierra Energy Inc. (“Gran Tierra” or the “Company”) (NYSE American:GTE)(TSX:GTE)(LSE:GTE) announces that the Company will release its 2024 fourth quarter and year ended December 31, 2024, financial and operating results on Monday, February 24, 2025, before market open. Gran Tierra will host its conference call on the same day, Monday, February 24, 2025, at 9:00 a.m. Mountain Time, 11:00 a.m. Eastern...
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Pr...
Beyond Air® Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update Revenues increased 34% compared to the previous quarter ended September 30, 2024; and exceeded $1 million Received CE Mark for LungFit PH® in Europe and Market Authorization in Australia; international shipments to commence later this year Conference call at 4:30 p.m. ET today, February 10th GARDEN CITY, New York, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessi...
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance w...
Beyond Air® Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement GARDEN CITY, N.Y., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced it received a notification from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has been granted an additional 180-day compliance period, or until August 4, 2025 to regain compliance with Nasdaq’s...
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conf...
Beyond Air® Schedules Third Fiscal Quarter 2025 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it plans to report the financial results for the fiscal third quarter 2025 ended December 31, 2024 on Monday, February 10, 2025 after the market closes. Conference Call & WebcastMonday, February 10th @ 4:30 PM ...
Beyond Air® Announces LungFit® PH Receives Market Authorization in Aus...
Beyond Air® Announces LungFit® PH Receives Market Authorization in Australia GARDEN CITY, N.Y., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the LungFit® PH has received market authorization from the Australian Therapeutic Goods Administration (TGA) for sale as a Class IIb medical device to deliver nitric oxide, a vasodilator, generated by the device into the inspira...
Gran Tierra Energy Inc. Reports Robust Reserves Replacement and Record...
Gran Tierra Energy Inc. Reports Robust Reserves Replacement and Record High Reserves Sixth Consecutive Year of 1P Total Reserves Growth Resulting in Highest Total Reserves in Company HistoryDelivered 702% 1P and 1,249% 2P Reserves Replacement Including Recent AcquisitionTotal Liquids 1P and 2P Reserves Increased to 128 and 217 Million Barrels of Oil Equivalent with 1P and 2P Reserve Life Index increasing to 10 and 17 Years, RespectivelyAdded Total Reserves of 89 MMBOE 1P, 159 MMBOE 2P and 191 MMBOE 3PNet Present Value Before Tax Discounted at 10% of $2.0 Billion (1P), $3.2 Billion (2P), and...
Gran Tierra Energy Inc. Announces 2025 Guidance and Operations Update
Gran Tierra Energy Inc. Announces 2025 Guidance and Operations Update 2025 Capital Expenditure Budget of $240-280 Million and Expected 2025 Cash Flow1 of $260-300 Million2025 Capital Program Includes 10-14 Development Wells and 6-8 High Impact Exploration WellsForecast 2025 Production of 47,000-53,000 BOEPD, Representing at the Midpoint, an Increase of 44% from 2024 Forecast 2025 Free Cash Flow2 of $90 Million Before Exploration, $20 Million After Exploration in Base CasePlan to Allocate Up To 50% of After Exploration Free Cash Flow to Share BuybacksAchieved Total Company Production for 202...
- Jonathan Moreland
ASA ASA
PETS PETMED EXPRESS INC.
FBK FB FINANCIAL CORPORATION
JELD JELD-WEN HOLDING INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
BIGZ BLACKROCK INNOVATION AND GROWTH TST
CVI CVR ENERGY
MIO INC.
PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
- Jonathan Moreland
- Jonathan Moreland
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ETON ETON PHARMACEUTICALS
RLAY RELAY THERAPEUTICS
BIGZ BLACKROCK INNOVATION AND GROWTH TST
BUKS BUTLER NATIONAL CORP
GLSI GREENWICH LIFESCIENCES INC
MEGI MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
MIO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM EATON VANCE INSD CALIF MUN BD FD
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthc...
Beyond Air to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 GARDEN CITY, N.Y., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Steve Lisi, Chairman and Chief Executive Officer of Beyond Air, will participate in one-on-one meetings and a presentation at the Lytham Partners 2025 Investor Healthcare Summit, taking place virtually on...
- Jonathan Moreland
CDXS CODEXIS
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
ANAB ANAPTYSBIO INC.
FUND ROYCE FOCUS TRUST
GRX INC.
ZYME THE GABELLI HEALTHCARE & WELLNESSRX TRUST
BIGZ ZYMEWORKS INC.
GLSI BLACKROCK INNOVATION AND GROWTH TST
MEGI GREENWICH LIFESCIENCES INC
TXO MAINSTAY CBRE GBL INFRASTRUCTURE MEGATRENDS FD
MORNINGSTAR PARTNERS
L.P.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.